Q4 2025 Cryoport Inc Earnings Call Transcript
Key Points
- CryoPort Inc (CYRX) reported full-year revenue from continuing operations of $176.2 million, exceeding the high end of their prior guidance.
- The company achieved double-digit growth in the fourth quarter, driven by expanding commercial cell and gene therapy activity.
- Revenue from commercial cell and gene therapy increased 29% year over year to a record $33.4 million.
- CryoPort Inc (CYRX) supported a record 760 clinical trials and 20 commercial therapies worldwide in 2025.
- The company anticipates achieving positive adjusted EBITDA in the second half of 2026.
- The financials of CRYOPDP, previously part of CryoPort's Life Sciences Services segment, are now presented as discontinued operations due to its sale to DHL.
- The macroeconomic environment remains volatile, posing potential risks to CryoPort Inc (CYRX)'s growth projections.
- MVE Biological Solutions, a segment of CryoPort Inc (CYRX), reported only 7% revenue growth year over year, indicating slower growth compared to other segments.
- The integration and full benefits of the strategic partnership with DHL are expected to take time to materialize.
- CryoPort Inc (CYRX) faces uncertainties in the timing of new product launches and their market adoption, which could impact future revenue projections.
(audio in progress)
(Operator Instructions) As a reminder, this call is being recorded.
I will now turn the call over to your host, Todd Fromer, from KCSA Strategic Communications. Please go ahead.
Thank you, operator. Before we begin today, I would like to remind everyone that this conference call contains certain forward-looking statements. All statements that address our operating performance, events or developments that we expect or anticipate occurring in the future are all forward-looking statements.
These forward-looking statements are based on management's beliefs and assumptions and not on information currently available to our management team. Our management team believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
